Compare Cintas Corporation (CTAS) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Danaher Corporation — how do they compare? Cintas Corporation trades at $205.28 (market cap $81.25B), while Danaher Corporation trades at $207.03 (market cap $147.18B). The key difference: Danaher Corporation is the larger of the two by market cap, and Cintas Corporation pays the higher dividend (1.02%). Which is the better fit depends on your goals.
| CTAS | DHR | |
|---|---|---|
Market Cap | $81.25B | $147.18B |
Sector | Industrials | Health |
52-Week High | $225.10 | $242.05 |
52-Week Low | $163.55 | $161.91 |
Enterprise Value | $83.67B | $169.39B |
Dividend Yield | 1.02% | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $203.05, up 0.45% on the day, with a bullish technical signal and strong fundamental performance. The company reported Q2 2026 EPS of $1.29, beating estimates, and revenue growth continues with a 17.75% net income margin. Recent news highlights Bank of America's upgrade to 'Buy' and a quarterly dividend announcement, reflecting confidence in its outlook.
The outlook for CTAS is positive, supported by consistent earnings beats and robust profitability, though high valuation multiples like a P/E of 41.35 pose a risk. Upside exists toward the consensus price target of $225.83, but investors should monitor competitive pressures and economic sensitivity.
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
